Name:
Dr Duncan Richards FBPhS
Organisation:
University of Oxford
Year elected:
2012
Primary professional setting:
Academia
Duncan Richards trained in medicine at Oxford University and after junior doctor roles in London, he returned to Oxford as Clinical Lecturer in Clinical Pharmacology. His DM thesis research was on a translational model using platelet ion flux to interrogate angiotensin biology and he is author of the Oxford Handbook of Practical Drug Therapy. Duncan joined GSK in 2003 and has worked in a number of clinical development roles from first in human to file and launch. Duncan is currently medicine development leader for anti-SAP for systemic amyloidosis having been Head of the Academic Discovery Performance Unit during its early clinical development. Duncan has recently also taken on the role of Director of GSK’s phase 1 and experimental medicine unit in Cambridge (CUC). Duncan has been a strong advocate for the role of experimental medicine in early drug development and chairs GSK’s Experimental Medicine Forum. Externally he is a member of the MRC/NIHR EME Board and serves on several committees of the British Pharmacological Society.